device

World’s First InterAtrial Shunt Proven to Reduce Heart Failure Symptoms.

Corvia Medical, Inc., is dedicated to revolutionizing the treatment of heart failure with first-in-class structural heart devices. The company has developed the world’s first transcatheter device designed to treat heart failure with preserved (HFpEF) or mid-range (HFmrEF) ejection fraction, previously known as diastolic heart failure (DHF). The innovative InterAtrial Shunt Device (IASD^®) is clinically proven to reduce elevated left atrial pressure (LAp), which is the main cause of heart failure symptoms.

Press Releases

October 9 2019

Corvia Medical’s Interatrial Shunt Device (IASD^®) Receives Breakthrough Device Designation For Heart Failure
March 11 2019

Corvia Medical Enters Into Agreement With Edwards Lifesciences, The Global Leader In Structural Heart Innovation TEWKSBURY, MA – March 11, 2019— Corvia Medical, Inc., a privately-held company with a first-in-class structural heart device to treat heart failure, today announced it has entered into an agreement with Edwards Lifesciences. The agreement includes a $35 million investment […]
August 27 2018

Corvia Medical Announces Strong Positive One-Year Data From Reduce LAP-HF I Randomized, Sham-Controlled Clinical Trial

Read All News >

Clinical Study Information

Corvia Medical is enrolling patients in the REDUCE LAP HF II Study. To learn more, visit treatmyheartfailure.com.

Hear From Our Patients

Hear About REDUCE LAP-HF I

Hear From Our Sites

Patients Eager to Test Device That Could Ease Heart Failure Symptoms

Ohio State Evaluates First Transcatheter Implant for Diastolic Heart Failure